[{"id":25894,"versionId":6324,"title":"February 2021","type":2,"subType":"0","childSubType":"","date":"2/22/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb-21.jpg","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-21.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eCoverage Guidelines Established for Rituximab-arrx (Riabni)\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25818,"versionId":6324,"title":"January 2021","type":2,"subType":"0","childSubType":"","date":"1/1/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-jan21.jpg","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-21.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Agalsidase Beta (Fabrazyme)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Lumasiran (Oxlumo)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Brexanolone (Zulresso)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25731,"versionId":6324,"title":"December 2020","type":2,"subType":"0","childSubType":"","date":"12/28/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-dec20.jpg","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Chemodenervation \u0026ndash; Botulinum Toxin\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Human Growth Hormone\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Electronystagmography (ENG) and Videonystagmography (VNG) Services\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25329,"versionId":6324,"title":"November 2020","type":2,"subType":"0","childSubType":"","date":"11/25/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-nov20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Pemetrexed (Alimta, Pemfexy)\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bevacizumab (Avastin) and Bevacizumab Biosimilars\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Programmed Death Receptor (PD-1)/ Programmed Death-Ligand (PD-L1) Blocking Antibodies\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":24634,"versionId":6324,"title":"October 2020","type":2,"subType":"0","childSubType":"","date":"10/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-oct20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bendamustine (Treanda, Bendeka, Belrapzo)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Brexucabtagene Autoleucel (Tecartus)\u003c/li\u003e\n\u003cli\u003eUpdated Criteria for Tumor Treatment Fields\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23928,"versionId":6324,"title":"September 2020","type":2,"subType":"0","childSubType":"","date":"9/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-sept20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Autonomic Nervous System Function Testing\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Private Duty Nursing\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Rituximab (Rituxan), Rituximab Biosimilars, and Rituximab and Hyaluronidase Human (Rituxan Hycela)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23561,"versionId":6324,"title":"August 2020","type":2,"subType":"0","childSubType":"","date":"8/31/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-aug20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Pegfilgrastim-apgf (Nyvepria)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Elosulfase alfa (Vimizim)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Daunorubicin and Cytarabine Liposomal (Vyxeos)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23115,"versionId":6324,"title":"July 2020","type":2,"subType":"0","childSubType":"","date":"7/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-july20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Leuprolide Acetate (Fensolvi)\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Sacituzumab Govitecan-hziy (Trodelvy)\u003c/li\u003e\n\u003cli\u003eRevised Coverage Criteria for Electroconvulsive Therapy\u003c/li\u003e\n\u003cli\u003eREMINDER: Cardiology \u0026amp; Radiology Imaging Clinical Guidelines\u003c/li\u003e\n\u003cli\u003eClinical Guidelines Revised for Trastuzumab (Herceptin)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22678,"versionId":6324,"title":"June 2020","type":2,"subType":"0","childSubType":"","date":"6/23/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-june20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Intravenous Anesthetics for Off-Label Indications\u003c/li\u003e\n\u003cli\u003eSeparate Policy Established for Biochemical Markers of Bone Remodeling\u003c/li\u003e\n\u003cli\u003eUpdated Policy Format for Assisted Reproductive Technology\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22380,"versionId":6324,"title":"May 2020","type":2,"subType":"0","childSubType":"","date":"5/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-may20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for IL-1 and IL-1b Blockers\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Eptinezumab-jjmr (Vyepti)\u003c/li\u003e\n\u003cli\u003eClinical Guidelines Established for Isatuximab-irfc (Sarclisa)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22239,"versionId":6324,"title":"April 2020","type":2,"subType":"0","childSubType":"","date":"4/20/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-apr20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Established for Coronavirus (COVID-19) Testing\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Givosiran (Givlaari)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Luspatercept (Reblozyl)\u003c/li\u003e\n\u003cli\u003eAnd more\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22009,"versionId":6324,"title":"March 2020","type":2,"subType":"0","childSubType":"","date":"3/30/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-mar20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Enfortumab Vedotin-ejfv (Padcev)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Leadless Cardiac Pacemakers\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCHIP Medical Necessity Policy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21797,"versionId":6324,"title":"February 2020","type":2,"subType":"0","childSubType":"","date":"2/23/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-20.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli style=\"text-align: left;\"\u003eCoverage Guidelines Revised for Intravitreal Injections\u003c/li\u003e\n\u003cli\u003eClinical Guidelines Revised for Testosterone Androgens\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Crizanlizumab-tmca (Adakveo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21665,"versionId":6324,"title":"January 2020","type":2,"subType":"0","childSubType":"","date":"1/27/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-jan20.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-20.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eClinical Guidelines Established for V-Go, Disposable Insulin Delivery Device; New Criteria Added for External Insulin Pumps\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Gonadotropin Releasing Hormones Analogs\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21430,"versionId":6324,"title":"December 2019","type":2,"subType":"0","childSubType":"","date":"12/17/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-dec19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-19.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Golimumab (Simponi, Simponi Aria)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Ustekinumab (Stelara)\u003c/li\u003e\n\u003cli\u003eFacility added for Prophylactic Mastectomy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21106,"versionId":6324,"title":"November 2019","type":2,"subType":"0","childSubType":"","date":"11/20/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-nov19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-19.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Levoleucovorin (Khapzory)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Elotuzumab (Empliciti)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20888,"versionId":6324,"title":"October 2019","type":2,"subType":"0","childSubType":"","date":"10/28/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-oct19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-19.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Fluocinolone Acetonide (Yutiq)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Obesity Policy\u003c/li\u003e\n\u003cli\u003eFacility added to Lung and Lobar Lung Transplantation\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20602,"versionId":6324,"title":"September 2019","type":2,"subType":"0","childSubType":"","date":"9/20/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-sept19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Daratumumab (Darzalex)\u003c/li\u003e\n\u003cli\u003eFacility Added to Dental Services\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Olaratumab (Lartruvo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20467,"versionId":6324,"title":"August 2019","type":2,"subType":"0","childSubType":"","date":"8/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-aug19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eClinical Guidelines Established for Polatuzumab Vedotin-piiq (Polivy)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Intra-Articular Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bendamustine (Treanda, Bendeka, Belrapzo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20314,"versionId":6324,"title":"July 2019","type":2,"subType":"0","childSubType":"","date":"7/25/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-july19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eInjectable Drugs Added to Site of Care\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Romosozumab-aqqg (Evenity)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Foot Orthotics for Conditions Other than Diabetes\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Brexanolone (Zulresso)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19794,"versionId":6324,"title":"June 2019","type":2,"subType":"0","childSubType":"","date":"6/24/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-june19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Trastuzumab (Herceptin)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bevacizumab (Avastin)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Updated for Preoperative Photographs\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19708,"versionId":6324,"title":"May 2019","type":2,"subType":"0","childSubType":"","date":"5/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-may19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Tildrakizumab (Ilumya)\u003c/li\u003e\n\u003cli\u003eClinical Guidelines Established for Calcitonin Gene-Related Peptide (CGRP) Inhibitors\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Golimumab (Simponi, Simponi Aria)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19568,"versionId":6324,"title":"April 2019","type":2,"subType":"0","childSubType":"","date":"4/29/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-apr19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Hemophilia Treatment Clotting Factors/Coagulant Blood Products\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-awwb (Mvasi)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised/Facility added for Extracorporeal Membrane Oxygenation (ECMO)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19489,"versionId":6324,"title":"March 2019","type":2,"subType":"0","childSubType":"","date":"3/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-mar19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Rituximab-abbs (Truxima)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Foot Orthotics for Conditions Other than Diabetes\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Granulocyte Colony Stimulating Factors (G-CSF)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19285,"versionId":6324,"title":"February 2019","type":2,"subType":"0","childSubType":"","date":"2/25/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Coverage Criteria for Alpha1-Proteinase Inhibitor Infusions\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Ocrelizumab (Ocrevus)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Reinstated for Donor Leukocyte Infusion for Hematologic Malignancies that\u0026nbsp;Relapse after Allogeneic Cell Transplant\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19225,"versionId":6324,"title":"January 2019","type":2,"subType":"0","childSubType":"","date":"1/28/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-jan19.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-19.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Eustachian Tube Balloon Dilation\u003c/li\u003e\n\u003cli\u003ePreferred Product Established for Anti-Vascular Endothelial Growth Factors (anti-VEGF), for the\u0026nbsp;Treatment of Ophthalmological Diseases\u003c/li\u003e\n\u003cli\u003ePreferred Products Established for Hyaluronic Acid Therapies for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17789,"versionId":6324,"title":"December 2018","type":2,"subType":"0","childSubType":"","date":"12/20/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-dec18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Developed for Patisiran (Onpattro)\u003c/li\u003e\n\u003cli\u003eREMINDER: Musculoskeletal and Pain Management Program Update\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17646,"versionId":6324,"title":"November 2018","type":2,"subType":"0","childSubType":"","date":"11/26/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-nov18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Histone Deacetylase (HDAC) Inhibitors\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Mogamulizumab-kpkc (Poteligeo)\u003c/li\u003e\n\u003cli\u003ePolymerized Sucralfate Malate Paste (ProThelial) Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eREMINDER: Molecular and Genomic Testing\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17551,"versionId":6324,"title":"October 2018","type":2,"subType":"0","childSubType":"","date":"10/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-oct18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eNew Policy Established for Site of Care for Certain Injectable Drugs\u003c/li\u003e\n\u003cli\u003eRevised Coverage Guidelines for Thermography (Thermogram)\u003c/li\u003e\n\u003cli\u003eREMINDER: Radiology and Cardiac Imaging Program\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17381,"versionId":6324,"title":"September 2018","type":2,"subType":"0","childSubType":"","date":"9/24/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-sept18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Heplisav\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Autonomic Nervous System Function Testing\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Treatment of the Prostate\u003c/li\u003e\n\u003cli\u003eRevised Coverage Criteria for Gender Reassignment Surgery\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17260,"versionId":6324,"title":"August 2018","type":2,"subType":"0","childSubType":"","date":"8/27/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-aug18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Updated for Hemophilia Treatment\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Nusinersen (Spinraza)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Vestronidase Alpha (Mepsevii)\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17141,"versionId":6324,"title":"July 2018","type":2,"subType":"0","childSubType":"","date":"7/30/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-july18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Ibalizumab-uiyk (Trogarzo)\\Coverage Criteria Revised for Wheelchairs and Wheelchair Accessories\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for the Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":16998,"versionId":6324,"title":"June 2018","type":2,"subType":"0","childSubType":"","date":"6/25/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-june18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Programmed Death Receptor (PD-1)/Programmed Death Ligand (PDL1)\u0026nbsp;Blocking Antibodies\u003c/li\u003e\n\u003cli\u003eRecommendations Established for Evidence-Based Practice\u003c/li\u003e\n\u003cli\u003eNew Coverage Criteria Established for Inhaled Nitric Oxide\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":16896,"versionId":6324,"title":"May 2018","type":2,"subType":"0","childSubType":"","date":"5/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-may18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Guidelines Revised for Azacitidine (Vidaza)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Guidelines Revised for Fulvestrant (Faslodex)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePlace of Service Revised for Total Hip and Total Knee Arthroplasty\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Brentuximab vedotin (Adcetris)\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":16810,"versionId":6324,"title":"April 2018","type":2,"subType":"0","childSubType":"","date":"4/30/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-apr18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eClinical Guidelines Revised for Bortezomib (Velcade)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Revised for Pneumatic Compression Devices\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNew Policy: Radiation Treatment with Lutathera\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":15271,"versionId":6324,"title":"March 2018","type":2,"subType":"0","childSubType":"","date":"3/22/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-mar18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Established for Infliximab-qbtx (Ixifi)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Revised for Cetuximab (Erbitux)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Position Established for GI Effects Comprehensive Stool Profile\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":14285,"versionId":6324,"title":"February 2018","type":2,"subType":"0","childSubType":"","date":"2/26/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography (DaT-SPECT/DaTscan)\u003c/li\u003e\n\u003cli\u003eCoverage for Occupational Therapy\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea for Adults - RETRACTED\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":14231,"versionId":6324,"title":"January 2018","type":2,"subType":"0","childSubType":"","date":"1/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-jan18.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-18.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Alpha1-Proteinase Inhibitor Infusions\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":13355,"versionId":6324,"title":"December 2017","type":2,"subType":"0","childSubType":"","date":"12/22/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-dec17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-17.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea for Adults\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Criteria Revised for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Transcatheter Aortic Valve Replacement (TAVR)\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":11140,"versionId":6324,"title":"November 2017","type":2,"subType":"0","childSubType":"","date":"11/27/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-nov17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-17.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eNew Coverage Criteria Established for Pralatrexate (Folotyn)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Artifical Intervertebral Disc Replacement\u003c/li\u003e\n\u003cli\u003eCriteria Established for the Use of Amniotic Membrane Products and Amniotic Fluid to Treat Diabetic Ulcerts and Ophthalmic Conditions\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":9119,"versionId":6324,"title":"October 2017","type":2,"subType":"0","childSubType":"","date":"10/30/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-oct17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-17.pdf","baseUrl":null,"urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Updated for Blinatumomab (Blincyto)\u003c/li\u003e\n\u003cli\u003eNew Policy: Medication Assisted Treatment (MAT) for Opioid Use Disorder: Methadone\u003c/li\u003e\n\u003cli\u003eREMINDER: Molecular and Genomic Testing\u003c/li\u003e\n\u003cli\u003eRadiology Management Program Update\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7783,"versionId":6324,"title":"September 2017","type":2,"subType":"0","childSubType":"","date":"9/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-sept17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Golimumab (Simponi, Simponi Aria)\u003c/li\u003e\n\u003cli\u003eChange in Policy Position for In Vitro Chemoresistance and Chemosensitivity Assays\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Electromyography (EMG)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7784,"versionId":6324,"title":"August 2017","type":2,"subType":"0","childSubType":"","date":"8/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-aug17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Confocal Laser Endomicroscopy\u003c/li\u003e\n\u003cli\u003eNew Policy Established for Lower Limb Prostheses\u003c/li\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Radiofrequency Ablation of Peripheral Nerves to Treat Chronic Knee Pain\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7785,"versionId":6324,"title":"July 2017","type":2,"subType":"0","childSubType":"","date":"7/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-july17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Changes for Paclitaxel, albumin-bound, Abraxane\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Laboratory Testing for Novel Influenza A (H1N1)\u003c/li\u003e\n\u003cli\u003eCriteria Updated for Acute Graft Versus Host Disease\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7786,"versionId":6324,"title":"June 2017","type":2,"subType":"0","childSubType":"","date":"6/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-june17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Eculizumab\u003c/li\u003e\n\u003cli\u003eCoverage for the Quadrivalent (RIV4) Influenza Virus Vaccine\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Bone Morphogenetic Protein\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7787,"versionId":6324,"title":"May 2017","type":2,"subType":"0","childSubType":"","date":"5/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-may17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eQuantity Limits for Breast Prosthesis and Mastectomy Bras\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Stereotactic Body Radiation Therapy\u003c/li\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Irinotecan Liposomal (Onivyde)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7788,"versionId":6324,"title":"April 2017","type":2,"subType":"0","childSubType":"","date":"4/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-apr17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eNew Coverage Position for Naltrexone Implant (or Pellets) for Treatment of Alcohol and Opioid Dependence\u003c/li\u003e\n\u003cli\u003eNew Coverage Position for Buprenorphine Implant for Treatment of Opioid Dependence\u003c/li\u003e\n\u003cli\u003eNew Policy Established for Ultra-Rapid Detoxification\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7789,"versionId":6324,"title":"March 2017","type":2,"subType":"0","childSubType":"","date":"3/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-mar17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Ipilimumab (Yervoy)\u003c/li\u003e\n\u003cli\u003eFacility Criteria Applied to Ilizarov Bone Lengthening\u003c/li\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Fibrin Sealants\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7790,"versionId":6324,"title":"February 2017","type":2,"subType":"0","childSubType":"","date":"2/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eNew Policy Established for Intracellular Micronutrient Testing Panel\u003c/li\u003e\n\u003cli\u003eNew Coverage Position for Upper Gastrointestinal Endoscopy\u003c/li\u003e\n\u003cli\u003eNew Clinical Criteria for Air Ambulance Services Policy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7791,"versionId":6324,"title":"January 2017","type":2,"subType":"0","childSubType":"","date":"1/1/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-jan17.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-17.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Bendamustine (Treanda) and Coverage Criteria Added for Bendamustine (Bendeka)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Mepolizumab (NUCALA) and Coverage Criteria Added for Reslizumab (CINQAIR)\u003c/li\u003e\n\u003cli\u003eCoverage for Removal of Skin Lesions\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7792,"versionId":6324,"title":"December 2016","type":2,"subType":"0","childSubType":"","date":"12/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eAbobotulinumtoxinA (DYSPORT) Now Covered for Lower Limb Spasticity in Pediatric Patients 2 Years of Age and Older\u003c/li\u003e\n\u003cli\u003eExondys 51 Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eNew Coverage Criteria for Omalizumab (Xolair)\u003c/li\u003e\n\u003cli\u003eREMINDER: Molecular and Genomic Testing\u003c/li\u003e\n\u003cli\u003eNew Coverage Criteria for Radiofrequency Facet Denervation\u003c/li\u003e\n\u003cli\u003eNew Pennsylvania Medicare Advantage Policy Number for Electrocardiographic Services\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7793,"versionId":6324,"title":"November 2016","type":2,"subType":"0","childSubType":"","date":"11/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eNew Coverage Position for Ramucirumab (Cyramza)\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Gender Reassignment Surgery\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Hematopoietic Stem Cell Transplantation for AL Amyloidosis (Primary Systemic Amyloidosis)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7794,"versionId":6324,"title":"October 2016","type":2,"subType":"0","childSubType":"","date":"10/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Intraoperative Neurophysiologic Monitoring; Facility Application Added \u0026ndash; RETRACTED\u003c/li\u003e\n\u003cli\u003eNew Policy Established For Assays for Vitamins and Metabolic Function\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7795,"versionId":6324,"title":"September 2016","type":2,"subType":"0","childSubType":"","date":"9/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eManipulation Services\u003c/li\u003e\n\u003cli\u003eNoncontact Ultrasound Therapy for Chronic Wound Management is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea in Adults\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7796,"versionId":6324,"title":"August 2016","type":2,"subType":"0","childSubType":"","date":"8/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCorrection: Coverage Criteria Revised for Trastuzumab (Herceptin)\u003c/li\u003e\n\u003cli\u003eClinical Criteria Has Been Created for the Dohlman Doane Boston KPro (Boston KPro) Artificial Cornea\u003c/li\u003e\n\u003cli\u003eHF10 Spinal Cord Stimulation Coverage Position Changing Oct. 31, 2016\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7797,"versionId":6324,"title":"July 2016","type":2,"subType":"0","childSubType":"","date":"7/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eBurn Criteria Added to Non-Custom/Custom-Made Gradient Compression Garments/Stockings/Sleeves\u003c/li\u003e\n\u003cli\u003eClinical Criteria Revised for Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eAlcohol Injection into Interdigital Neuromas for the Treatment of Peripheral Nerve Pain Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7798,"versionId":6324,"title":"June 2016","type":2,"subType":"0","childSubType":"","date":"6/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Home Apnea Monitors\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Hybrid Cardiac Ablation Procedure\u003c/li\u003e\n\u003cli\u003eRevised Criteria and Title Change for Endovascular Aneurysm Repair\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7799,"versionId":6324,"title":"May 2016","type":2,"subType":"0","childSubType":"","date":"5/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for the Use of PAP Devices\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Gemcitabine HCl (Gemzar)\u003c/li\u003e\n\u003cli\u003eCyanoacrylate Adhesive (e.g., VenaSeal Closure System) is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7800,"versionId":6324,"title":"April 2016","type":2,"subType":"0","childSubType":"","date":"4/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Ultrasound Use in the Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eDocetaxel (Taxotere) No Longer Covered for the Treatment of Penile Cancer\u003c/li\u003e\n\u003cli\u003eClinical Criteria Revised for the Testing for Lyme Disease\u003c/li\u003e\n\u003cli\u003eProducts Approved for Treatment of Diabetic Lower Extremity Ulcers\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7801,"versionId":6324,"title":"March 2016","type":2,"subType":"0","childSubType":"","date":"3/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eMedically Necessary Modifiers Added to Coverage Requirements for Routine Foot Care and Debridement of Mycotic/Hypertrophic Nails\u003c/li\u003e\n\u003cli\u003eUrolift for Benign Prostatic Hypertrophy to be Considered Medically Necessary When Coverage Criteria Are Met\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Coverage of Mastectomy and Reconstructive Surgery\u003c/li\u003e\n\u003cli\u003eHCPCS Quarterly Coding Updates\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7802,"versionId":6324,"title":"February 2016","type":2,"subType":"0","childSubType":"","date":"2/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Multi-gene Expression Assay for Predicting Recurrence in Colon Cancer\u003c/li\u003e\n\u003cli\u003eSurgical Treatment of Lymphedema Added to Medical Policy Y-11, Treatments for Lymphedema\u003c/li\u003e\n\u003cli\u003eUpdated Criteria for Cardiac Rehabilitation Program, Phase II Outpatient\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Coverage of Magnetic Resonance Imaging (MRI) of the Breast\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7803,"versionId":6324,"title":"January 2016","type":2,"subType":"0","childSubType":"","date":"1/1/2016","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-16.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Human Growth Hormone\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Immunotherapy for Prostate Cancer\u003c/li\u003e\n\u003cli\u003ePolicy Criteria Revised for Genetic Testing for Hereditary Breast and/or Ovarian Cancer\u003c/li\u003e\n\u003cli\u003eTimed Therapy Codes\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7804,"versionId":6324,"title":"December 2015","type":2,"subType":"0","childSubType":"","date":"12/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-dec-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Outpatient Pulmonary Rehabilitation\u003c/li\u003e\n\u003cli\u003eNew Policy on PCSK9 Inhibitors\u003c/li\u003e\n\u003cli\u003eSurgical Treatment of Lymphedema Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003cli\u003e\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7805,"versionId":6324,"title":"November 2015","type":2,"subType":"0","childSubType":"","date":"11/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-nov-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Immune Globulin Therapy\u003c/li\u003e\n\u003cli\u003eClinical Criteria Established for Coverage of Testosterone Androgens\u003c/li\u003e\n\u003cli\u003eCoverage Criteria for Cardiac Ablation Procedures Have Changed\u003c/li\u003e\n\u003cli\u003eBraces and Supports Guidelines Added\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7806,"versionId":6324,"title":"October 2015","type":2,"subType":"0","childSubType":"","date":"10/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-oct-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eDigital Breast Tomosynthesis Coverage Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Genetic Testing\u003c/li\u003e\n\u003cli\u003eMeniscal Allograft Transplantation Criteria Revised\u003c/li\u003e\n\u003cli\u003eUnderstanding When to Use New Patient vs Established Patient Evaluation and Management Codes\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7807,"versionId":6324,"title":"September 2015","type":2,"subType":"0","childSubType":"","date":"9/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eHCPCS Quarterly Coding Updates\u003c/li\u003e\n\u003cli\u003eHighmark Specialty Subcommittee Opportunity\u003c/li\u003e\n\u003cli\u003eObstetrical Ultrasound Criteria Revised\u003c/li\u003e\n\u003cli\u003eDiagnosis and Treatment of Sacroiliac Joint Pain Coverage Criteria Revised\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7808,"versionId":6324,"title":"August 2015","type":2,"subType":"0","childSubType":"","date":"8/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-aug-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eConservative Therapy First-Line Treatment for Stress Urinary Incontinence\u003c/li\u003e\n\u003cli\u003eElectrical Nerve Stimulation Updated\u003c/li\u003e\n\u003cli\u003eOVA1 Assay for Ovarian Cancer Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eInhalation Products for the Management of Cystic Fibrosis\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7809,"versionId":6324,"title":"July 2015","type":2,"subType":"0","childSubType":"","date":"7/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-july-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eQuantity Level Limits for Diabetic Test Strips and Lancets are Increased\u003c/li\u003e\n\u003cli\u003eElectrical Nerve Stimulation Updated\u003c/li\u003e\n\u003cli\u003eEmergency Room, Emergency Medical Care/Urgent Care, and Emergency Accident Care Policy Delayed\u003c/li\u003e\n\u003cli\u003eUltrasound Guidance Limitation\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7810,"versionId":6324,"title":"June 2015","type":2,"subType":"0","childSubType":"","date":"6/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-june-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eObesity Criteria Revised\u003c/li\u003e\n\u003cli\u003eSupervision of Preparation and Provision of Single or Multiple Antigens Clarified\u003c/li\u003e\n\u003cli\u003eCriteria Updated for Intra-articular Hyaluronan Injections\u003c/li\u003e\n\u003cli\u003eDosing Limits for Stelara to be Enforced for Prior Authorization Requests as of August 3, 2015\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7811,"versionId":6324,"title":"May 2015","type":2,"subType":"0","childSubType":"","date":"5/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-may-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eAdditional Tests Added to Medical Policy L-34, Genetic Testing\u003c/li\u003e\n\u003cli\u003eNew Policy for Selected Tests for Rheumatic Disease\u003c/li\u003e\n\u003cli\u003eOncotypeDX Gene Expression Assay for Prostate Cancer Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eNew Criteria for Non-Invasive Vascular Diagnostic Studies\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7812,"versionId":6324,"title":"April 2015","type":2,"subType":"0","childSubType":"","date":"4/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-apr-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Passive Motion Machines\u003c/li\u003e\n\u003cli\u003eNew Medical Policy on Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCologuard Multi-Target Stool Test is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Laminectomy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7813,"versionId":6324,"title":"March 2015","type":2,"subType":"0","childSubType":"","date":"3/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-mar-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Sleep Studies\u003c/li\u003e\n\u003cli\u003eNew Criteria for Mastectomy and Reconstructive Surgery\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eNew Procedure Code and Modifiers for Reporting\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7814,"versionId":6324,"title":"February 2015","type":2,"subType":"0","childSubType":"","date":"2/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-feb-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Repository Corticotropin Intramuscular Injection (H.P. Acthar Gel) Applicable to Both Facility and Professional\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Pharmacologic Treatment of Pulmonary Hypertension\u003c/li\u003e\n\u003cli\u003eAdditional Criteria Added for Testing and Treatment of Lyme Disease\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7815,"versionId":6324,"title":"January 2015","type":2,"subType":"0","childSubType":"","date":"1/1/2015","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-jan-15.pdf","baseUrl":null,"urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Alemtuzumab (Lemtrada)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Fulvestrant (Faslodex)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Nivolumab (Opdivo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2}]